急性上消化道出血112例临床疗效分析

采用国家中医药管理局颁布的《中医血证治疗常规》治疗急性上消化道出血112例，取得了较好疗效，总有效率达94．6％。进行了证和疗效，原发病和疗效，病情程度和疗关系的分析。说明中医血证治疗效常规在临床实践中是切实可行的。     

徐蔚霖治疗女童性早熟用药经验

儿童性早熟目前尚无理想的治疗方法。徐蔚霖认为，性早熟病在冲任，源在肝肾，治疗重在调理冲任和肝肾，尤应以疏肝理气为主，用药以入肝经药为先。对肾阴亏虚、相火亢盛患儿，加用滋阴补肾清火类药。对肝经湿热、气机郁滞患儿，酌加清热凉血、利湿化浊之品。用药当注意顾护脾胃，提出间歇服药这一特色方法     

大部脾栓塞术对重型地中海贫血患儿免疫功能影响的研究

目的评估大部脾栓塞术后重型地中海贫血患儿免疫功能的变化。方法对６２例患儿行脾大部栓塞术。结果ＩｇＧ在术后１周（１３±４ｇ／Ｌ）和术前（１６±６ｇ／Ｌ）差异有显著意义（Ｐ＜０．０５），术后３周恢复术前水平（１６±５ｇ／Ｌ）。ＩｇＡ、ＩｇＭ术前及术后各周均无明显差异。Ｔ细胞亚群中总Ｔ细胞数术前（４９±１２）和术后（６０±１２）差异有非常显著意义（Ｐ＜０．０１）。Ｔ辅助淋巴细胞（ＴＨ）术前（３８±９）与术后（４５±７）比较差异有非常显著意义（Ｐ＜０．０１）。ＴＨ／ＴＳ比值术后（１．６±０．３）与术前（１．２９±０．４）比较差异有非常显著意义（Ｐ＜０．０１），而Ｔ抑制淋巴细胞（Ｔｓ）术后（２９±７）与术前（３１±６）比较差异无显著意义（Ｐ＞０．０５）。纤维连接蛋白术后（２４８±７８）与术前（１１８±４１）比较差异有显著意义（Ｐ＜０．０５）。结论ＰＳＥ后免疫功能在术后３周迅速恢复     

刺五加注射液治疗脑出血的临床评价

30例高血压脑出血患者在常规疗法基础上加用紫外线辐射血液疗法作为对照组,另30例在上述疗法基础上加用刺五加注射液静脉滴注为治疗组。结果治疗组显效率96.7％,总有效率100％,对照组显效率60.0％,总有效率83.3％,治疗组明显优于对照组(P<0.01)。表明刺五加注射液不仅用于缺血性脑梗塞的治疗,而且也可用于脑出血,对出血量在30ml以下的病例,疗效较好。     

新型多功能前列腺治疗仪和临床应用

目前前列腺疾病是男性的常见疾病和多发病,已引起全社会的广泛重视。当前治疗该疾病的方法主要有药物治疗、手术治疗和物理治疗。本文介绍了一种新型前列腺治疗仪,该仪器通过射频电流作用于患处,使病变组织升温,加快局部血液循环起到杀灭病菌、清除炎症之能效,从而达到治疗目的。同时探头内设有震动装置和静磁场,促进病变部位坏死脱落细胞组织的排泄,同时不影响病变周围的正常组织。该仪器安全、有效,是一种值得推广的产品。该仪器应用于临床100例,患者均取得了良好的治疗效果。     

介入化疗治疗子宫颈癌49例分析

[目的]评价经子宫动脉介入灌注化疗对子宫颈癌的疗效及并发症.[方法]49例子宫颈癌采用Seldinger技术,经右侧股动脉穿刺并分别插管至左、右子宫动脉行灌注化疗.[结果]介入治疗后症状缓解率为100.0%,均行根治术.46例患者可观察到肿块体积明显缩小,总有效率为93.8%.[结论]经子宫动脉灌注化疗可作为根治术前常规的辅助方法.     

TRAIL与羟基喜树碱联用协同杀伤人肺腺癌A549细胞

目的：探讨羟基喜树碱与肿瘤坏死因子相关凋亡诱导配体（tumor necrosis factor-related apoptosis inducing ligand，TRAIL）联用对肺腺癌A549细胞是否具有协同杀伤作用，并对其机制进行初步研究。方法：MTT法检测细胞毒性作用，流式细胞仪检测细胞凋亡和线粒体膜电位，Western blot分析bcl-2和bcl-xl蛋白水平变化。结果：单用100ng／mL TRAIL，4、40和400μg／mL羟基喜树碱对A549细胞杀伤率分别为13．9％、3．0％、23．4％和76．7％，联合用药的抑制率分别为43．6％、52．5％和83．1%。100ng／mL TRAIL和4μg/mL羟基喜树碱有协同作用，可使细胞线粒体膜电住降低，但不影响bcl-2和bcl-xl蛋白表达。结论：TRAIL与羟基喜树碱联用对肺腺癌A549细胞有明显的协同杀伤作用，其机制可能与羟基喜树碱降低A549细胞线粒体膜电位有关。     

Impact of EGFR expression on colorectal cancer patient prognosis and survival.

BACKGROUND: Epidermal growth factor receptor (EGFR) is overexpressed in many types of cancers, especially colorectal cancer (CRC), and seems to reflect more aggressive histological and clinical behaviors. The aim of this study was to evaluate EGFR immunohistochemical reactivity in CRC biopsies, and to analyze its relationship with various histological and clinical characteristics and survival. PATIENTS AND METHODS: A composite EGFR score, obtained by multiplying the grade (% positive cells) by the intensity of labeling (0-9) was used to define patients with low or high EGFR expression whose clinicopathological features were then compared. Univariate tests and multivariate Cox proportional hazards model were applied for data analysis. RESULTS: Tissue sections from 150 CRC patients with a median follow-up of 40 months were examined. Median patient age at diagnosis was 70 years (range 38-89 years). EGFR reactivity was positive for 143 patients (97%) and high for 118 (80%). According to multivariate analysis, EGFR overexpression was significantly associated with tumor stage, with a higher percentage of EGFR overexpression in T3 than T4 (P=0.003) and not with overall survival. CONCLUSIONS: EGFR was overexpressed in this CRC patient population and was significantly associated with TNM (tumor-node-metastasis) stage T3. In the context of a new therapeutic strategy using EGFR-targeted therapies, although EGFR remains a controversial prognostic factor, this expression-stage association may play a crucial role in a decision to initiate an adjuvant treatment.